Keryx Biopharmaceuticals (KERX) : Mizuho Securities Usa reduced its stake in Keryx Biopharmaceuticals by 89.7% during the most recent quarter end. The investment management company now holds a total of 31,700 shares of Keryx Biopharmaceuticals which is valued at $163,255 after selling 276,200 shares in Keryx Biopharmaceuticals , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Keryx Biopharmaceuticals makes up approximately 0.04% of Mizuho Securities Usa’s portfolio.
Keryx Biopharmaceuticals opened for trading at $5.01 and hit $5.19 on the upside on Wednesday, eventually ending the session at $5.08, with a gain of 0.40% or 0.02 points. The heightened volatility saw the trading volume jump to 14,45,057 shares. Company has a market cap of $538 M.
Other Hedge Funds, Including , Fox Run Management L.l.c. sold out all of its stake in KERX during the most recent quarter. The investment firm sold 20,000 shares of KERX which is valued $103,000. Heritage Investors Management Corp added KERX to its portfolio by purchasing 17,500 company shares during the most recent quarter which is valued at $88,550. Keryx Biopharmaceuticals makes up approx 0.01% of Heritage Investors Management Corp’s portfolio. Pure Financial Advisors added KERX to its portfolio by purchasing 20,000 company shares during the most recent quarter which is valued at $93,800. Keryx Biopharmaceuticals makes up approx 0.03% of Pure Financial Advisors’s portfolio.
On the company’s financial health, Keryx Biopharmaceuticals reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on Feb 25, 2016. Analyst had a consensus of $-0.25. The company had revenue of $5.80 million for the quarter, compared to analysts expectations of $5.82 million. The company’s revenue was up 866.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.
Many Wall Street Analysts have commented on Keryx Biopharmaceuticals. Company shares were Reiterated by FBR Capital on Mar 30, 2016 to “Outperform”, Firm has raised the Price Target to $ 13 from a previous price target of $10 .FBR Capital Upgraded Keryx Biopharmaceuticals on Feb 29, 2016 to ” Outperform”, Price Target of the shares are set at $10.Shares were Reiterated by Stifel on Feb 26, 2016 to “Buy” and Lowered the Price Target to $ 9 from a previous price target of $10 .
Keryx Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate) an oral absorbable iron-based compound received marketing approval from the United States Food and Drug Administration (FDA) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels Auryxia’s pharmacodynamic properties resulted in increased ferritin iron and transferrin saturation (TSAT).